Corcept Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Corcept Therapeutics (Menlo Park, CA): 2 reconciled FDA prescription therapies, $409.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterMenlo Park, CA
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$409.6M
2024 Medicare Part D Spend$341.8M
2024 Medicaid Spend$67.8M
California HCAI SB 17 Filings6 WAC filings (max 25.8% 2-yr change)